BNN — BRAIN Biotech AG Share Price
0.000.00%
Last trade - 00:00- €46.97m
- €48.18m
- €56.23m
- 30
- 28
- 16
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.87 | ||
| Price to Tang. Book | 2.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.52% | ||
| Return on Equity | -44.22% | ||
| Operating Margin | -10.53% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 40.05 | 39.06 | 39.22 | 50.3 | 56.23 | 59.2 | 66.78 | 14.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BRAIN Biotech AG, formerly known as BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company develops and brings to market biological ingredients for Nutrition & Health, SkinCare and Industrial BioSolutions. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.
Directors
- Georg Kellinghusen CSU (75)
- Adriaan Moelker CMG
- Anna Eichhorn VSU (50)
- Lukas Linnig CFO (29)
- Michael Krohn EVP (59)
- Martin Langer EVP (57)
- Ute Dechert VPR (60)
- Stephen Catling IND
- Michael Majerus IND (60)
- Bernhard Hauer SUB (67)
- Wiltrud Treffenfeldt SUB
- Last Annual
- September 30th, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 21st, 2000
- Public Since
- February 9th, 2016
- No. of Employees
- 309
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
- Frankfurt Stock Exchange
- Shares in Issue
- 21,847,495
- Address
- Darmstaedter Strasse 34-36, ZWINGENBERG, 64673
- Web
- https://www.brain-biotech.com/de
- Phone
- +49 625193310
- Contact
- Martina Schuster
- Auditors
- Baker Tilly Gmbh & Co. KG
Upcoming Events for BNN
Q4 2024 BRAIN Biotech AG Earnings Release
Q1 2025 BRAIN Biotech AG Earnings Release
BRAIN Biotech AG Annual Shareholders Meeting
Similar to BNN
AIS AG
Frankfurt Stock Exchange
Alba SE
Frankfurt Stock Exchange
edding AG
Frankfurt Stock Exchange
Evertec
Frankfurt Stock Exchange
Libero football finance AG
Frankfurt Stock Exchange
FAQ
What is the BRAIN Biotech AG share price?
As of Today at 19:41 UTC, shares in BRAIN Biotech AG are trading at €2.12. This share price information is delayed by 15 minutes.
How has the BRAIN Biotech AG share price performed this year?
Shares in BRAIN Biotech AG last closed at €2.12 and the price had moved by -51.24% over the past 365 days. In terms of relative price strength the BRAIN Biotech AG share price has underperformed the FTSE Global All Cap Index by -58.17% over the past year.
What are the analyst and broker recommendations for BRAIN Biotech AG?
The overall consensus recommendation for BRAIN Biotech AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BRAIN Biotech AG dividend yield?
BRAIN Biotech AG does not currently pay a dividend.
Does BRAIN Biotech AG pay a dividend?
BRAIN Biotech AG does not currently pay a dividend.
When does BRAIN Biotech AG next pay dividends?
BRAIN Biotech AG does not currently pay a dividend.
How do I buy BRAIN Biotech AG shares?
To buy shares in BRAIN Biotech AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BRAIN Biotech AG?
As of the previous close price of €2.12, shares in BRAIN Biotech AG had a market capitalisation of €46.97m.
Where are BRAIN Biotech AG shares listed?
Here are the trading details for BRAIN Biotech AG:
- Country of listing: Germany
- Exchange: FRA
- Ticker Symbol: BNN
What kind of share is BRAIN Biotech AG?
Based on an overall assessment of its quality, value and momentum BRAIN Biotech AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BRAIN Biotech AG share price forecast for 2024?
The analyst consensus target price for shares in BRAIN Biotech AG is €8.10. That is 282.08% above the last closing price of €2.12.
Analysts covering BRAIN Biotech AG currently have a consensus Earnings Per Share (EPS) forecast of -€0.37 for the next financial year.
Find out moreWhat is the trend in the BRAIN Biotech AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BRAIN Biotech AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -39.77%.
As of the last closing price of €2.12, shares in BRAIN Biotech AG were trading -25.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BRAIN Biotech AG PE Ratio?
The BRAIN Biotech AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €2.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BRAIN Biotech AG?
BRAIN Biotech AG's management team is headed by:
- Georg Kellinghusen - CSU
- Adriaan Moelker - CMG
- Anna Eichhorn - VSU
- Lukas Linnig - CFO
- Michael Krohn - EVP
- Martin Langer - EVP
- Ute Dechert - VPR
- Stephen Catling - IND
- Michael Majerus - IND
- Bernhard Hauer - SUB
- Wiltrud Treffenfeldt - SUB